A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional ...

More than four decades into the HIV epidemic, progress has transformed treatment and prevention, yet the need remains urgent.

Recognizing the signs of mild cognitive impairment meant Di could start treatment earlier to help slow her Alzheimer's ...

A 52-week extension study showed that the drug continues to maintain favorable body composition with no safety issues.

The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...

The FDA has expanded approval of dupilumab to include children aged 2 to 11 years with chronic spontaneous urticaria who ...

Sanofi ( SNY) and Regeneron’s ( REGN) Dupixent was approved in the U.S. as the first biologic medicine for young children ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

Once-weekly lonapegsomatropin shows sustained safety and efficacy up to 90 weeks in adults with GHD, according to AACE 2026 ...

If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS– ...

Approach could help patients avoid often debilitating surgeries, early study suggests ...